Heart rate reduction with ivabradine in patients with acute decompensated systolic heart failure

American Journal of Cardiovascular Drugs

Volumn 14, Issue 3, 2014, Pages 229-235

  Sargento, Luis ^a   Satendra, Milan ^a   Longo, Susana ^a   Lousada, Nuno ^a   Dos Reis, Roberto Palma ^a  

^a Lisbon   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; IVABRADINE; BENZAZEPINE DERIVATIVE; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE DECOMPENSATED SYSTOLIC HEART FAILURE; ACUTE HEART FAILURE; ADULT; ARTICLE; BRADYCARDIA; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEART RATE REDUCTION; HUMAN; LONGITUDINAL STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; NEW YORK HEART ASSOCIATION CLASS; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; RESTING HEART RATE; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HEART FAILURE; ACUTE DISEASE; AGED; BLOOD PRESSURE; DRUG EFFECTS; HEART FAILURE, SYSTOLIC; INTENSIVE CARE UNIT; METABOLISM; MIDDLE AGED; TIME; VERY ELDERLY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BENZAZEPINES; BLOOD PRESSURE; FEMALE; HEART FAILURE, SYSTOLIC; HEART RATE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; TIME FACTORS;

EID: 84904263518     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-013-0060-1     Document Type: Article

References (32)

1. Levy RL, White PD, et al. Transient tachycardia; prognostic significance alone and in association with transient hypertension. Med Press Egypt. 1946;38:207-12.
2. Wilhelmsen L, Berglund G, Elmfeldt D, et al. The multifactor primary prevention trial in Goteborg, Sweden. Eur Heart J. 1986;7:279-88. (Pubitemid 16120809)
3. Cooney MT, Vartiainen E, Laatikainen T, et al. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J. 2010;159:612-9.
4. Bohm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376:886-94.
5. Hoke RS, Muller-Werdan U, Lautenschlager C, et al. Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational study. Clin Res Cardiol. 2012;101:139-47.
6. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J. 2007;153:98-104. (Pubitemid 44880871)
7. Kjekshus J. Heart rate reduction - a mechanism of benefit? Eur Heart J. 1987;8(Suppl L):115-22. (Pubitemid 18088422)
8. Kjekshus JK. Importance of heart rate in determining betablocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol. 1986;57:43F-9F. (Pubitemid 16054097)
9. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J. 2007;28:3012-9. (Pubitemid 350262265)
10. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebocontrolled study. Lancet. 2010;376:875-85.
11. Tardif JC, O'Meara E, Komajda M, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32:2507-15.
12. Ekman I, Chassany O, Komajda M, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011;32:2395-404.
13. Volterrani M, Cice G, Caminiti G, et al. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol. 2011;151:218-24.
14. f current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004;64:1757-65.
15. De Ferrari GM, Mazzuero A, Agnesina L, et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail. 2008;10:550-5.
16. Kondrat'ev AI, Dolgikh VT, Stotskiǐ AO. Efficacy of ivabradine in combination therapy for complicated acute coronary syndrome in patients with type 2 diabetes mellitus. Ter Arkh. 2010;82(1):27-31.
17. Fasullo S, Cannizzaro S, Maringhini G, et al. Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings. J Card Fail. 2009;15:856-63.
18. Steg P, Lopez-de-Sà E, Schiele F, Hamon M, Meinertz T, Goicolea J, Werdan K, Lopez-Sendon J. VIVIFY (eValuation of the IntraVenous If inhibitor ivabradine after STsegment elevation mYocardial infarction) investigators. Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot study. Eur Heart J Acute Cardiovasc. Care. 2013;2(3):270-9.
19. Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100(3):149-55. (Pubitemid 37465145)
20. De Ferrari GM, Mazzuero A, Agnesina L, Bertoletti A, Lettino M, Campana C, Schwartz PJ, Tavazzi L. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail. 2008;10(6):550-5.
21. Camm AJ, Lau CP. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D. 2003;4(2):83-9. (Pubitemid 37062655)
22. Vitale D, De Santis V, Guarracino F, Fontana A, Pellegrini F, Tritapepe L. Use of ivabradine in catecholamine-induced tachycardia after high-risk cardiac surgery. Clin Res Cardiol. 2010;99(12):853-5.
23. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787-847.
24. Reil JC, Tardif JC, Ford I, Lloyd SM, O'Meara E, Komajda M, Borer JS, Tavazzi L, Swedberg K, Böhm M. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol. 2013;62(21):1977-85.
25. Post F, Münzel T. Ivabradine - a new therapeutic option for cardiogenic shock? Herz. 2009;34:224-9.
26. Riccioni G. Ivabradine: an intelligent drug for the treatment of ischemic heart disease. Molecules. 2012;17(11):13592-604.
27. Rognoni A, Bertolazzi M, Macciò S, Rognoni G. Ivabradine: cardiovascular effects. Cardiovasc Drug Discov. 2009;4:61-6.
28. De Santis V, Vitale D, Santoro A, Magliocca A, Porto AG, Nencini C, Tritapepe L. Ivabradine: potential clinical applications in critically ill patients. Clin Res Cardiol. 2013;102(3):171-8.
29. Borer JS, Le Heuzey JY. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor. Am J Ther. 2008;15(5):461-73.
30. Ekman I, Chassany O, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Swedberg K. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011;32(19):2395-404.
31. Riccioni G, Prencipe G, Benvenuto A, Masciocco L, Ventra S, Rizzo U, Russi C, Speziale G. Ivabradine improves all aspects of quality of life assessed with the 36-item short form health survey in subjects with chronic ischemic heart disease compared with beta-blockers. Pharmacology. 2013;91:35-8.
32. Sargento L, Satendra M, Longo S, et al. Early NT-proBNP decrease with ivabradine in ambulatory patients with systolic heart failure. Clin Cardiol. 2013;365:677-82.